Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 1/20 | 0.56 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6855436 | 0.88 | BCL9 (0.56) | BCL9CTNNB1GAAMGLLALDH1A1 | |
| SCHEMBL14495188 | 0.85 | BCL9 (0.59) | BCL9CTNNB1GAAMGLLALDH1A1 | |
| SCHEMBL15908462 | 0.83 | BCL9 (0.56) | BCL9CTNNB1GAAMGLLALDH1A1 | |
| SCHEMBL20931042 | 0.82 | BCL9 (0.59) | BCL9CTNNB1GAAMGLLALDH1A1 | |
| SCHEMBL1533872 | 0.82 | BCL9 (0.52) | BCL9CTNNB1GAAMGLLALDH1A1 | |
| SCHEMBL4941164 | 0.81 | ELANE (0.61) | BCL9CTNNB1GAAMGLLALDH1A1 | |
| SCHEMBL3310085 | 0.80 | GAA (0.58) | BCL9CTNNB1GAAMGLLALDH1A1 | |
| SCHEMBL21853704 | 0.78 | GAA (0.57) | BCL9CTNNB1GAAMGLLALDH1A1 | |
| SCHEMBL27301103 | 0.78 | GAA (0.57) | BCL9CTNNB1GAAMGLLALDH1A1 | |
| SCHEMBL12691183 | 0.78 | ELANE (0.54) | BCL9CTNNB1GAAMGLLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10413594-B2 | Conjugates of somatostatin analogues | PROLYNX LLC (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180296648-A1 | CONJUGATES OF SOMATOSTATIN ANALOGUES | PROLYNX LLC (US) | 2018-10-18 | — | — | US | disclosed |
| US-10086049-B2 | Conjugates of somatostatin analogues | PROLYNX LLC (US) | 2018-10-02 | — | — | US | disclosed |
| CN-106232131-A | Conjugates of somatostatin and analogs thereof | 普洛林克斯有限责任公司 | 2016-12-14 | — | — | CN | disclosed |
| US-20160271227-A1 | CONJUGATES OF SOMATOSTATIN ANALOGUES | PROLYNX LLC (US) | 2016-09-22 | — | — | US | disclosed |
| EP-3060230-A1 | CONJUGATES OF SOMATOSTATIN AND ITS ANALOGS | Prolynx LLC (US) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015061503-A1 | CONJUGATES OF SOMATOSTATIN AND ITS ANALOGS | PROLYNX LLC (US) | 2015-04-30 | — | — | WO | disclosed |
| US-7803816-B2 | MCH receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | disclosed |
| EP-1934199-B1 | INDANE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-04-22 | — | — | EP | disclosed |
| CN-101273026-A | Indane derivatives as MCH receptor antagonists | HOFFMANN LA ROCHE (CH) | 2008-09-24 | — | — | CN | disclosed |
| EP-1934199-A2 | INDANE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039462-A2 | INDANE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078165-A1 | MCH receptor antagonists | BERTHEL STEVEN J | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078165-A1 | MCH receptor antagonists | MCHR1, MCHR2, MC5R | BCL9 4291/4885CTNNB1 3436/4885GAA 1229/4885 |
| US-20180296648-A1 | CONJUGATES OF SOMATOSTATIN ANALOGUES | SSTR4, SSTR3, SSTR2 | BCL9 3918/4885CTNNB1 4818/4885GAA 593/4885 |
| US-20160271227-A1 | CONJUGATES OF SOMATOSTATIN ANALOGUES | SSTR4, SSTR3, SSTR2 | BCL9 3918/4885CTNNB1 4818/4885GAA 593/4885 |
| US-10413594-B2 | Conjugates of somatostatin analogues | SSTR4, SSTR3, SSTR2 | BCL9 3918/4885CTNNB1 4818/4885GAA 593/4885 |
| US-10086049-B2 | Conjugates of somatostatin analogues | SSTR4, SSTR3, SSTR2 | BCL9 3918/4885CTNNB1 4818/4885GAA 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.